Under this call 12 EU-OPENSCREEN-DRIVE partner institutions will each offer one predefined screening technology to external users. The user will provide the biological question and the related assay matching the offered techniques. The technologies have been selected carefully to demonstrate the broad variety of capacities and expertise that can be provided by the EU-OPENSCREEN network. Read more about EU-OPENSCREEN here: https://www.eu-openscreen.eu/services/screening.html.
The technologies are divided into three access tracks representing increasing levels of biological complexity, ranging from isolated proteins, cellular systems up to organoids and engineered micro tissues. Applicants from institutions within European member states and associated countries, are invited to apply to the one track which is most suitable to their individual assay setup and biological question. Up to two projects of scientists from Non-EU countries can also be funded. EU-OPENSCREEN will provide its collection of 100,000 chemical compounds for each of the 12 selected user projects as an in-kind contribution.
EU-OPENSCREEN-DRIVE offers transnational access to state-of-the-art small molecule screening facilities for rapid high throughput screening at the following EU-OPENSCREEN-DRIVE partner sites:
The project, funded under the European Union´s research and innovation programme Horizon 2020 ensuring long-term sustainability of excellence in chemical biology within Europe (EU-OPENSCREEN-DRIVE), will provide researchers with access to cutting-edge European small-molecule screening, medicinal chemistry and chemoproteomics facilities.
The EU-OPENSCREEN-DRIVE Kick-off meeting took place in Berlin on February 18, 2019. Participants from 33 project partners from all over Europe and from all partner sites of EU-OPENSCREEN met at the MDC Conference Centre on Campus Buch to ‘drive’ forward the implementation of the EU-OPENSCREEN operations, and to enhance our capabilities further.
EU-OPENSCREEN-DRIVE offers 23 fully funded research projects in the areas of chemoproteomics, small molecule screening and medicinal chemistry. Eligible proposals will be evaluated by external reviewers, and successful applicants will be selected in an open and transparent process. Transnational access comprises a total of 6 chemoproteomics, 12 small molecule screening and 5 medicinal chemistry projects.
EU-OPENSCREEN ERIC, the European Research Infrastructure Consortium for Chemical Biology, is the coordinating entity for EU-OPENSCREEN-DRIVE and responsible for the management of the transnational access calls.
Upcoming calls will be available at http://www.drive.eu-openscreen.eu
The small molecule screening call will be launched on June 1, 2019, and will be open until September 30, 2019, 20:00 CET, please check our website for details.
Funded transnational access user projects in the field of small molecule screening at EU-OPENSCREEN-DRIVE partner sites (incl personnel costs for partner site staff, partially consumables and travel costs).
Tanja Miletic and Katja Herzog from the EU-OPENSCREEN team are happy to answer specific questions. Please get in touch by email at: email@example.com.